Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for prevention and management of oral mucositis in nasopharyngeal carcinoma
ChiCTR2400081900Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in nasopharyngeal carcinoma (NPC) and stomatitis, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of severe oral mucositis. Started Mar 2024; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
nasopharyngeal carcinoma (NPC)stomatitis
Beyond the preview
Go deeper on ChiCTR2400081900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081900.